XNCR
Xencor, Inc.
NASDAQ · USHealthcareBiotechnology
$18.81+7.67%
Price as of Jul 20, 2026
XNCR financials
Xencor, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $125.6M | $110.5M | $174.6M | $164.6M |
| Cost of revenue | $10.5M | $227.7M | $0.00 | $199.6M |
| Gross profit | $115.1M | -$117.2M | $174.6M | -$35.0M |
| Operating expenses | $292.6M | $61.2M | $307.0M | $47.5M |
| Operating income | -$177.5M | -$178.4M | -$132.4M | -$82.5M |
| Net income | -$91.9M | -$232.6M | -$133.1M | -$55.2M |
| EBITDA | -$47.0M | -$186.2M | -$102.0M | -$45.7M |
| Basic EPS | $-1.24 | $-3.58 | $-2.08 | $-0.93 |
| Diluted EPS | $-1.24 | $-3.58 | $-2.08 | $-0.93 |
| Balance sheet | ||||
| Cash & equivalents | $54.1M | $40.9M | $53.8M | $53.9M |
| Total assets | $875.5M | $951.9M | $952.7M | $846.3M |
| Total liabilities | $239.9M | $277.9M | $283.6M | $118.8M |
| Stockholders’ equity | $635.6M | $677.6M | $668.8M | $727.5M |
| Total debt | $187.7M | $232.0M | $83.4M | $59.6M |
| Net debt | $133.7M | $191.1M | $29.6M | $5.7M |
| Cash flow | ||||
| Operating cash flow | -$135.1M | -$202.2M | -$77.9M | $24.5M |
| Capital expenditure | -$3.1M | -$6.1M | -$18.4M | -$43.4M |
| Free cash flow | -$138.3M | -$208.3M | -$96.4M | -$18.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |